Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 833-845

  Bocci, Guido ^a,b   Fioravanti, Anna ^a   Orlandi, Paola ^a   di Desidero, Teresa ^a   Natale, Gianfranco ^a   Fanelli, Giovanni ^a   Viacava, Paolo ^a   Naccarato, Antonio Giuseppe ^a   Francia, Giulio ^c   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CD31 ANTIGEN; CERAMIDE DERIVATIVE; CERAMIDE DERIVATIVE AL6; CERAMIDE DERIVATIVE C2; CERAMIDE DERIVATIVE C6; CERAMIDE DERIVATIVE C8; CYCLIN D1; GEMCITABINE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84866555540     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12772     Document Type: Article

References (67)

1. Asuthkar S, Rao JS, and Gondi CS (2012). Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs 21, 143-152.
2. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, and Kakolyris S (2011). Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 81, 259-272.
3. Penel N, Adenis A, and Bocci G (2012). Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82, 40-50.
4. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, and Del Tacca M (2005). Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16, 1243-1252.
5. Pasquier E, Kavallaris M, and Andre N (2010). Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7, 455-465.
6. Laquente B, Vinals F, and Germa JR (2007). Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 9, 93-98.
7. Kerbel RS and Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436.
8. Bocci G, Nicolaou KC, and Kerbel RS (2002). Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62, 6938-6943.
9. Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, and Scharovsky OG (2010). The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 18, 601-605.
10. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, and Cheng WF (2010). Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18, 1233-1243.
11. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al. (2012). Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61, 353-362.
12. Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, et al. (2012). Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15, 275-286.
13. Nelius T, Rinard K, and Filleur S (2011). Oral/metronomic cyclophosphamidebased chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 37, 444-455.
14. Italiano A, Toulmonde M, Lortal B, Stoeckle E, Garbay D, Kantor G, Kind M, Coindre JM, and Bui B (2010). "Metronomic" chemotherapy in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 66, 197-202.
15. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, and Katz MH (2010). Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9, 2068-2078.
16. Cham KK, Baker JH, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, et al. (2010). Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103, 52-60.
17. Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, Galan M, Ribas IG, Germa JR, Capella G, and Vinals F (2008). Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7, 638-647.
18. Perry DK and Kolesnick RN (2003). Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 115, 345-354.
19. Chatterjee S, Kolmakova A, and Miller M (2006). The role of the phospholipid sphingomyelin in heart disease. Curr Opin Investig Drugs 7, 219-228.
20. Claria J (2006). Regulation of cell proliferation and apoptosis by bioactive lipid mediators. Recent Pat Anticancer Drug Discov 1, 369-382.
21. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, and Ogretmen B (2010). Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6, 1603-1624.
22. Hannun YA and Obeid LM (2002). The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277, 25847-25850.
23. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, and Hannun YA (2002). De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 277, 12587-12595.
24. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, et al. (1996). Requirement for ceramide-initiated SAPK/ JNK signalling in stress-induced apoptosis. Nature 380, 75-79.
25. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z, and Kolesnick R (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86, 189-199.
26. Liu YY, Han TY, Giuliano AE, and Cabot MC (1999). Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274, 1140-1146.
27. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, et al. (2008). A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22, 2541-2551.
28. Liu YY, Han TY, Giuliano AE, and Cabot MC (2001). Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15, 719-730.
29. Patwardhan GA and Liu YY (2011). Sphingolipids and expression regulation of genes in cancer. Prog Lipid Res 50, 104-114.
30. Macchia M, Barontini S, Bertini S, Di Bussolo V, Fogli S, Giovannetti E, Grossi E, Minutolo F, and Danesi R (2001). Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. J Med Chem 44, 3994-4000.
31. Geley S, Hartmann BL, and Kofler R (1997). Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Lett 400, 15-18.
32. Jarvis WD, Grant S, and Kolesnick RN (1996). Ceramide and the induction of apoptosis. Clin Cancer Res 2, 1-6.
33. Kolesnick R and Hannun YA (1999). Ceramide and apoptosis. Trends Biochem Sci 24, 224-225.
34. Macchia M, Bertini S, Fogli S, Giovannetti E, Minutolo F, Rapposelli S, and Danesi R (2003). Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Farmaco 58, 205-211.
35. Giovannetti E, Leon LG, Bertini S, Macchia M, Minutolo F, Funel N, Alecci C, Giancola F, Danesi R, and Peters GJ (2010). Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 29, 419-426.
36. Bocci G, Danesi R, Del Tacca M, and Kerbel RS (2003). Selective antiendothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyltransferase inhibitor. Eur J Pharmacol 477, 17-21.
37. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, and Taraboletti G (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2, 1843-1849.
38. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, and Thompson TC (2003). Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9, 3653-3659.
39. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, et al. (2008). Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98, 1619-1629.
40. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, and Peters GJ (1995). Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22, 42-46.
41. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, Evangelista G, Montruccoli G, and Bevilacqua G (2004). Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol 204, 140-146.
42. Scholzen T and Gerdes J (2000). The Ki-67 protein: from the known and the unknown. J Cell Physiol 182, 311-322.
43. Viacava P, Bocci G, Tonacchera M, Fanelli G, DeServi M, Agretti P, Berti E, Goletti O, Aretini P, Resta ML, et al. (2007). Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 17, 191-197.
44. Kim HJ, Oh JE, Kim SW, Chun YJ, and Kim MY (2008). Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells. Cancer Lett 260, 88-95.
45. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, Jin YH, Wang QJ, Gu XJ, Bi ZG, et al. (2011). C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis 2, e117.
46. Bonnaud S, Niaudet C, Pottier G, Gaugler MH, Millour J, Barbet J, Sabatier L, and Paris F (2007). Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 67, 1803-1811.
47. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, Fuks Z, Gaugler MH, Kolesnick R, and Paris F (2010). Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res 70, 9905-9915.
48. Bocci G, Francia G, Man S, Lawler J, and Kerbel RS (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100, 12917-12922.
49. Bussolati B, Assenzio B, Deregibus MC, and Camussi G (2006). The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl) 84, 852-863.
50. Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, and Benjamin LE (2004). Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 3, 402-405.
51. Mirochnik Y, Kwiatek A, and Volpert OV (2008). Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 9, 851-862.
52. Cohen AW, Hnasko R, Schubert W, and Lisanti MP (2004). Role of caveolae and caveolins in health and disease. Physiol Rev 84, 1341-1379.
53. Lee SW, Reimer CL, Oh P, Campbell DB, and Schnitzer JE (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16, 1391-1397.
54. Fiucci G, Ravid D, Reich R, and Liscovitch M (2002). Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21, 2365-2375.
55. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, and Lisanti MP (2000). Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 275, 20717-20725.
56. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, and Lisanti MP (2003). Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14, 1027-1042.
57. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, Chopra NG, Scherer PE, Pestell RG, and Lisanti MP (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279, 51630-51646.
58. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, et al. (2000). The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275, 21203-21209.
59. Ruvolo PP (2001). Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 15, 1153-1160.
60. Coroneos E, Wang Y, Panuska JR, Templeton DJ, and Kester M (1996). Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochem J 316(pt 1), 13-17.
61. Bourbon NA, Yun J, Berkey D, Wang Y, and Kester M (2001). Inhibitory actions of ceramide upon PKC-e{open}/ERK interactions. Am J Physiol Cell Physiol 280, C1403-C1411.
62. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, and Danesi R (2005). Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93, 319-330.
63. Fioravanti A, Canu B, Ali G, Orlandi P, Allegrini G, Di Desidero T, Emmenegger U, Fontanini G, Danesi R, Del Tacca M, et al. (2009). Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol 619, 8-14.
64. Hackl C, Man S, Francia G, Milsom C, Xu P, and Kerbel RS (2012). Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. doi:10.1136/gutjnl-2011-301585.
65. Stover T and Kester M (2003). Liposomal delivery enhances short-chain ceramideinduced apoptosis of breast cancer cells. J Pharmacol Exp Ther 307, 468-475.
66. Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, et al. (2012). Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 11, 680-689.
67. Desai A, Vyas T, and Amiji M (2008). Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 97, 2745-2756.